3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Melanoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Head and Neck Carcinoma
1
Glioblastoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
pembrolizumab
47
Cisplatin
24
Cetuximab
23
Paclitaxel
18
Nivolumab
18
Radiotherapy
15
Docetaxel
15
Carboplatin
14
Fluorouracil
11
tremelimumab
7
durvalumab
7
Erlotinib Hydrochloride
6
avelumab
5
Radiotherapy, Intensity-Modulated
5
Radiosurgery
5
Pemetrexed
4
Ipilimumab
4
Immunoglobulin G
4
Gemcitabine
4
Fulvestrant
4
Capecitabine
4
Bevacizumab
4
epacadostat
3
cemiplimab
3
atezolizumab
3
Taxes
3
Radiation
3
Everolimus
3
Cyclophosphamide
3
Amifostine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Squamous Cell Carcinoma of Head and Neck
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled